AI Article Synopsis

  • Recent research highlights the role of the T-cell differentiation protein 2 (MAL2) as a key regulator in various cancers, with a focus on its expression and function in ovarian cancer (OC).
  • Data from multiple databases, including GEPIA and Kaplan-Meier, reveal MAL2's association with patient survival, mutations, and its influence on drug sensitivity across different cancer types.
  • Experimental investigations using CRISPR/Cas9 to knock out MAL2 in OC cell lines demonstrate that its absence inhibits cell proliferation, migration, and invasion, suggesting MAL2 acts as an oncogene that facilitates epithelial-mesenchymal transition (EMT) in OC.

Article Abstract

Recent studies have reported that T-cell differentiation protein 2 (MAL2) is an important regulator in cancers. Here, we downloaded data from multiple databases to analyze MAL2 expression and function in pan-cancers, especially in ovarian cancer (OC). Gene Expression Profiling Interactive Analysis (GEPIA) databases was used to examine MAL2 expression in 13 types of cancer. Kaplan-Meier plotter database was used to analyze the overall survival rate of MAL2 in pan-cancers. The Catalog of Somatic Mutations in Cancer (COSMIC), cBioPortal, and UCSC databases were used to examine MAL2 mutation in human cancers. Metascape, STRING, and GeneMANIA websites were used to explore MAL2 function in OC. Furthermore, ggplot2 package and ROC package were performed to analyze hub gene expression and undertake receiver operating characteristic (ROC) analysis. Drug sensitivity of MAL2 in OC was examined by the GSCALite database. In order to verify the results from databases above, real-time quantitative polymerase chain reaction (qRT-PCR) and western blotting were conducted to detect the expression of MAL2 in OC cells. CRISPR/Cas9 system was used to knockout the MAL2 gene in the OC cell lines HO8910 and OVCAR3, using specific guide RNA targeting the exons of MAL2. Then, we performed proliferation, colony formation, migration, and invasion assays to investigate the impact of MAL2 in OC cell lines and . Epithelial-mesenchymal transition (EMT)-associated biomarkers were significantly altered via western blotting and qRT-PCR. Taken together, we observed that MAL2 was remarkably dysregulated in multiple cancers and was related to patient overall survival (OS), mutation, and drug sensitivity. Furthermore, experimental results showed that MAL2 deletion negatively regulated the proliferation, migration, invasion, and EMT of OC, indicating that MAL2 is a novel oncogene that can activate EMT, significantly promote both the proliferation and migration of OC and , and provide new clues for treatment strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803135PMC
http://dx.doi.org/10.3389/fcell.2021.736649DOI Listing

Publication Analysis

Top Keywords

mal2
15
human cancers
8
mal2 expression
8
gene expression
8
databases examine
8
examine mal2
8
drug sensitivity
8
western blotting
8
cell lines
8
migration invasion
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!